Skip to main content
. 2019 Dec 12;11(23):11111–11123. doi: 10.18632/aging.102513

Table 1. Demographic and clinical characteristics of the training cohort.

Characteristic Variable A09≤9%(n=61) A09>9%(n=649)
Gender Female/Male 4/57 141/508
Age years±SD 54.62±11.02 51.69± 11.42
stratified AFP 40–100/100–400/400–1000/1000~ 21/24/7/9 109/172/125/243
HBsAg -/+ 6/55 95/554
HBV DNA 0/3/4/5/6 28/12/12/8/1 344/124/93/75/13
HCV -/+ 61/0 643/6
Ascites mild/middle/large 48/13/0 573/74/2
HLNE -/+ 57/4 646/3
Liver cirrhosis -/+ 6/55 102/547
Tumor number 1/>1 47/14 507/142
Tumor capsular imcomplete/complete 19/42 258/391
TMD cm 4.37±2.84 4.89±3.23
PBT -/+ 59/2 630/19
Differentiation poor/moderate/well 0/46/15 13/538/98
MVI -/+ 42/19 446/203
AFP ng/mL ± SD 1954.49±6558.55 3274.63±7588.34
AFPDAY 0.07±0.02 0.14±0.06
E50time day 11.78±20.47 3.92±0.92
WBC 1 × 109/L ± SD 5.94±2.95 5.62±2.62
PLT 1 × 109/L ± SD 119.79±55.94 143.94±60.64
PA g/L± SD 0.20±0.06 0.21±0.05
TB umol /L ± SD 13.27±5.86 12.71±5.28
ALB g/L± SD 40.38±2.86 40.70±3.31
ALT U/L ± SD 68.89±186.11 43.92±77.62
GGT U/L ± SD 79.62±58.49 75.25±73.93
ALP U/L ± SD 87.85±32.99 82.77±33.79
CEA ng/mL ± SD 2.78±1.59 2.56±2.09
CA19-9 U/mL ± SD 35.80±40.25 22.70±22.53

Values are presented as n (%) or mean ± standard deviation(SD).

Abbreviation: ALT: alanine transaminase, AFP: alpha fetoprotein, CEA: carcinoembryonic antigen, CA19 -9: carbohydrate antigen 19 -9, HBsAg: hepatitis B surface antigen, HCV: anti-hepatitis C virus, HLNE: Hilar lymph node enlargement, TMD: tumor maximum dimension, MVI: microvascular invasion, AFPDAY: daily decrease of post-operation/preoperative AFP, E50time:half-life of AFP, WBC: white blood cell, PLT: blood platelet, PA: prealbumin, TB: total bilirubin, ALB: albumin, GGT: gamma-glutamyltransferase, ALP: alkaline phosphatase, HBV DNA 0/3/4/5/6:*100/3/4/5/6